KTE-X19治疗复发难治成人B细胞急性淋巴细胞白血病的ZUMA-3研究2期结果
ZUMA-3是一项国际多中心单臂开放标签2期研究,评估自体抗CD19 CAR-T疗法KTE-X19在复发难治B前体急性淋巴细胞白血病成人患者中的疗效与安全性。
要点
- KTE-X19在复发难治B-ALL成人中完全缓解率71%,MRD阴性率97%。
- ≥3级不良事件常见贫血49%、发热36%,细胞因子释放综合征24%。
核心结论
- KTE-X19在复发难治B前体急性淋巴细胞白血病成人患者中显示高完全缓解率,缓解者中位总生存未达到,安全性可控。
研究设计与样本
- 国际多中心单臂开放标签2期研究,在美国、加拿大和欧洲25个中心入组71例患者。
- eligible患者年龄≥18岁,ECOG体能状态0-1,骨髓形态学疾病(原始细胞>5%)。
- 经白细胞分离和预处理化疗后,接受单次KTE-X19输注(1×10^6 CAR T细胞/kg体重)。
- 主要终点为中央评估的总体完全缓解或伴不完全血液学恢复的完全缓解率。
主要发现
- 缓解者中位总生存未达到,38例(97%)患者达到MRD阴性。
- 10例(18%)患者在KTE-X19输注后接受异基因干细胞移植巩固。
- ≥3级不良事件最常见为贫血(27例[49%])和发热(20例[36%]),≥3级感染14例(25%),≥3级细胞因子释放综合征13例(24%),≥3级神经系统事件14例(25%),2例5级KTE-X19相关事件(脑疝和感染性休克)。
临床怎么用
- KTE-X19可作为复发难治B前体急性淋巴细胞白血病成人患者的治疗选择,需关注细胞因子释放综合征和神经系统事件。
局限性
- 单臂开放标签设计,无对照臂,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite treatment with novel therapies and allogeneic stem-cell transplant (allo-SCT) consolidation, outcomes in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia remain poor, underlining the need for more effective therapies. METHODS: We report the pivotal phase 2 results of ZUMA-3, an international, multicentre, single-arm, open-label study evaluating the efficacy and safety of the autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy KTE-X19 in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia. Patients were enrolled at 25 sites in the USA, Canada, and Europe. Eligible patients were aged 18 years or older, with Eastern Cooperative Oncology Group performance status of 0-1, and morphological disease in the bone marrow (>5% blasts). After leukapheresis and conditioning chemotherapy, patients received a single KTE-X19 infusion (1 × 106 CAR T cells per kg bodyweight). The primary endpoint was the rate of overall complete remission or complete remission with incomplete haematological recovery by central assessment. Duration of remission and relapse-free survival, overall survival, minimal residual disease (MRD) negativity rate, and allo-SCT rate were assessed as secondary endpoints. Efficacy and safety analyses were done in the treated population (all patients who received a dose of KTE-X19). This study is registered with ClinicalTrials.gov, NCT02614066. FINDINGS: Between Oct 1, 2018, and Oct 9, 2019, 71 patients were enrolled and underwent leukapheresis. KTE-X19 was successfully manufactured for 65 (92%) patients and administered to 55 (77%). The median age of treated patients was 40 years (IQR 28-52). At the median follow-up of 16·4 months (13·8-19·6), 39 patients (71%; 95% CI 57-82, p<0·0001) had complete remission or complete remission with incomplete haematological recovery, with 31 (56%) patients reaching complete remission. Median duration of remission was 12·8 months (95% CI 8·7-not estimable), median relapse-free survival was 11·6 months (2·7-15·5), and median overall survival was 18·2 months (15·9-not estimable). Among responders, the median overall survival was not reached, and 38 (97%) patients had MRD negativity. Ten (18%) patients received allo-SCT consolidation after KTE-X19 infusion. The most common adverse events of grade 3 or higher were anaemia (27 [49%] patients) and pyrexia (20 [36%] patients). 14 (25%) patients had infections of grade 3 or higher. Two grade 5 KTE-X19-related events occurred (brain herniation and septic shock). Cytokine release syndrome of grade 3 or higher occurred in 13 (24%) patients and neurological events of grade 3 or higher occurred in 14 (25%) patients. INTERPRETATION: KTE-X19 showed a high rate of complete remission or complete remission with incomplete haematological recovery in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia, with the median overall survival not reached in responding patients, and a manageable safety profile. These findings indicate that KTE-X19 has the potential to confer long-term clinical benefit to these patients. FUNDING: Kite, a Gilead Company.
引用
- Shah BD, Ghobadi A, Oluwole OO, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021. PMID: 34097852. doi:10.1016/S0140-6736(21)01222-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。